Pfizer admits defeat on AstraZeneca bid
US pharmaceuticals giant Pfizer has called off its multi-billion pound bid to take over British-Swedish firm AstraZeneca. The decision came after AstraZeneca's board declined an offer worth almost £70bn.
AstraZeneca shareholder believes Pfizer will renew bid
AstraZeneca shareholder Aberdeen Asset Management believes Pfizer will return with a renewed bid for the British drug manufacturer in six months.
ITV News Business Editor Joel Hills reports:
-
AstraZeneca: It ain't over until the 26th...
Pfizer has until Monday until it admits defeat in bidding for AstraZeneca. But after the shenanigans of the past few days we cannot be sure.
-
Is Pfizer's pursuit of AstraZeneca finally over?
AstraZeneca's share price is tumbling back down to earth after the board rejected a "final" Pfizer bid. So is the takeover really over?
-
How should we regard Pfizer's promises?
Sweden's Finance Minister says the Government should be "very, very sceptical" about any promises the US pharmaceutical giant makes.